elotuzumab,bortezomib,lenalidomide
abbvie,merck,Takeda
['swog-1211', 'elotuzumab']
#cedarssinaicancer at #asco22. dr. brian durie is co-author on the poster randomized phase ii trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple #myeloma (swog-1211). 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.